{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:34:12Z","timestamp":1761708852778},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,1,17]],"date-time":"2013-01-17T00:00:00Z","timestamp":1358380800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1007\/s00105-012-2526-5","type":"journal-article","created":{"date-parts":[[2013,1,15]],"date-time":"2013-01-15T14:55:21Z","timestamp":1358261721000},"page":"190-194","source":"Crossref","is-referenced-by-count":9,"title":["CD30-positives anaplastisch gro\u00dfzelliges T-Zell-Lymphom unter immunsuppressiver Therapie einer Pityriasis rubra pilaris mit Ustekinumab"],"prefix":"10.1007","volume":"64","author":[{"given":"D.","family":"Humme","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Beyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.-J.","family":"R\u00f6wert-Huber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Sterry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Philipp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,1,17]]},"reference":[{"key":"2526_CR1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/pds.2046","volume":"20","author":"Askling","year":"2011","unstructured":"Askling J, Fahrbach K, Nordstrom B et al (2011) Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 20(2):119\u2013130","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2526_CR2","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/art.21675","volume":"54","author":"Baecklund","year":"2006","unstructured":"Baecklund E, Iliadou A, Askling J et al (2006) Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54(3):692\u2013701","journal-title":"Arthritis Rheum"},{"key":"2526_CR3","first-page":"1071","volume":"7","author":"Barth","year":"2009","unstructured":"Barth D, Harth W, Treudler R, Simon JC (2009) Successful treatment of pityriasis rubra pilaris (type 1) under combination of infliximab and methotrexate. J Dtsch Dermatol Ges 7(12):1071\u20131074","journal-title":"J Dtsch Dermatol Ges"},{"key":"2526_CR4","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1136\/ard.2008.094904","volume":"68","author":"Bongartz","year":"2009","unstructured":"Bongartz T, Warren FC, Mines D et al (2009) Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis 68(7):1177\u20131183","journal-title":"Ann Rheum Dis"},{"key":"2526_CR5","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","volume":"295","author":"Bongartz","year":"2006","unstructured":"Bongartz T, Sutton AJ, Sweeting MJ et al (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295(19):2275\u20132285","journal-title":"JAMA"},{"key":"2526_CR6","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1002\/art.10679","volume":"46","author":"Brown","year":"2002","unstructured":"Brown SL, Greene MH, Gershon SK et al (2002) Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the food and drug administration. Arthritis Rheum 46(12):3151\u20133158","journal-title":"Arthritis Rheum"},{"key":"2526_CR7","doi-asserted-by":"crossref","unstructured":"Gordon KB, Papp KA, Langley RG et al (2011) Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol [Epub ahead of print]","DOI":"10.1016\/j.jaad.2011.06.041"},{"key":"2526_CR8","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1001\/archdermatol.2011.213","volume":"147","author":"Jung","year":"2011","unstructured":"Jung J, Levin EC, Jarrett R et al (2011) Lymphomatoid drug reaction to ustekinumab. Arch Dermatol 147(8):992\u2013993","journal-title":"Arch Dermatol"},{"key":"2526_CR9","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2340\/00015555-0728","volume":"89","author":"Koens","year":"2009","unstructured":"Koens L, Senff NJ, Vermeer MH et al (2009) Cutaneous gamma\/delta T-cell lymphoma during treatment with etanercept for rheumatoid arthritis. Acta Derm Venereol 89(6):653\u2013654","journal-title":"Acta Derm Venereol"},{"key":"2526_CR10","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/archdermatol.2008.526","volume":"145","author":"Lafaille","year":"2009","unstructured":"Lafaille P, Bouffard D, Provost N (2009) Exacerbation of undiagnosed mycosis fungoides during treatment with etanercept. Arch Dermatol 145(1):94\u201395","journal-title":"Arch Dermatol"},{"key":"2526_CR11","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1046\/j.1365-2133.2003.05384.x","volume":"149","author":"Mah\u00e9","year":"2003","unstructured":"Mah\u00e9 E, Descamps V, Grossin M et al (2003) CD30\u2009+ T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab. Br J Dermatol 149(1):170\u2013173","journal-title":"Br J Dermatol"},{"key":"2526_CR12","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1136\/ard.2010.149419","volume":"70","author":"Mariette","year":"2011","unstructured":"Mariette X, Matucci-Cerinic M, Pavelka K et al (2011) Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 70(11):1895\u20131904","journal-title":"Ann Rheum Dis"},{"key":"2526_CR13","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jaad.2008.05.037","volume":"59","author":"M\u00fcller","year":"2008","unstructured":"M\u00fcller H, Gattringer C, Zelger B et al (2008) Infliximab monotherapy as first-line treatment for adult-onset pityriasis rubra pilaris: case report an review of the literature on biologic therapy. J Am Acad Dermatol 59(5 Suppl):S65\u2013S70","journal-title":"J Am Acad Dermatol"},{"key":"2526_CR14","first-page":"S1","volume":"9","author":"Nast","year":"2011","unstructured":"Nast A, Boehncke WH, Mrowietz U et al (2011) S3-guidelines for the treatment of psoriasis vulgaris. Update 2011. J Dtsch Dermatol Ges 9(Suppl 2):S1\u2013S104","journal-title":"J Dtsch Dermatol Ges"},{"key":"2526_CR15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/120347541201600305","volume":"16","author":"Papp","year":"2012","unstructured":"Papp KA, Dekoven J, Parsons L et al (2012) Biologic therapy in psoriasis: perspectives on associated risks and patient management. J Cutan Med Surg 16(3):153\u2013168","journal-title":"J Cutan Med Surg"},{"key":"2526_CR16","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1097\/MEG.0b013e32834bb90a","volume":"23","author":"Parakkal","year":"2011","unstructured":"Parakkal D, Sifuentes H, Semer R, Ehrenpreis ED (2011) Hepatosplenic T-cell lymphoma in patients receiving TNF-\u03b1 inhibitor therapy: expanding the groups at risk. Eur J Gastroenterol Hepatol 23(12):1150\u20131156","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2526_CR17","doi-asserted-by":"crossref","first-page":"402","DOI":"10.18553\/jmcp.2010.16.6.402","volume":"16","author":"Schafer","year":"2010","unstructured":"Schafer JA, Kjesbo NK, Gleason PP (2010) Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis. J Manag Care Pharm 16(6):402\u2013416","journal-title":"J Manag Care Pharm"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-012-2526-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-012-2526-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-012-2526-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,6]],"date-time":"2022-02-06T00:52:54Z","timestamp":1644108774000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-012-2526-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,17]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["2526"],"URL":"https:\/\/doi.org\/10.1007\/s00105-012-2526-5","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,17]]}}}